• Explore /
  • Poster
  • / Genetic variant of TWEAK to predict clinical outcome in mCRC patients (pts) treated with first line FOLFIRI and Bevacizumab (FOLFIRI/BEV) in FIRE-3 and TRIBE cohorts.

Genetic variant of TWEAK to predict clinical outcome in mCRC patients (pts) treated with first line FOLFIRI and Bevacizumab (FOLFIRI/BEV) in FIRE-3 and TRIBE cohorts.

Abstract Poster

Authors

null

Anish Parekh

Norris Comprehensive Cancer Center of USC, Los Angeles, CA

Anish Parekh , Yan Ning , Sebastian Stintzing , Fotios Loupakis , Wu Zhang , Dongyun Yang , Yu Sunakawa , Stefan Stremitzer , Satoshi Matsusaka , Satoshi Okazaki , Rita Elkhoueiry , Angela Mendez , Afsaneh Barzi , Marta Schirripa , Volker Heinemann , Heinz-Josef Lenz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer

Citation

J Clin Oncol 33, 2015 (suppl; abstr 3554)

DOI

10.1200/jco.2015.33.15_suppl.3554

Abstract #

3554

Poster Bd #

46

Abstract Disclosures

Similar Posters

First Author: Yan Ning

First Author: Alberto Puccini

First Author: Leonor Benhaim

First Author: Wu Zhang